Shaanxi Meibang Pharmaceutical Group Co., Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 471.43 million compared to CNY 617.07 million a year ago. Revenue was CNY 476.15 million compared to CNY 617.65 million a year ago.

Net income was CNY 73.61 million compared to CNY 116.98 million a year ago. Basic earnings per share from continuing operations was CNY 0.54 compared to CNY 0.87 a year ago. Diluted earnings per share from continuing operations was CNY 0.54 compared to CNY 0.87 a year ago.